Advertisement
U.S. markets open in 3 hours 22 minutes
  • S&P Futures

    5,303.75
    -4.50 (-0.08%)
     
  • Dow Futures

    40,137.00
    -7.00 (-0.02%)
     
  • Nasdaq Futures

    18,478.50
    -25.25 (-0.14%)
     
  • Russell 2000 Futures

    2,135.50
    -2.90 (-0.14%)
     
  • Crude Oil

    81.91
    +0.56 (+0.69%)
     
  • Gold

    2,217.50
    +4.80 (+0.22%)
     
  • Silver

    24.57
    -0.19 (-0.76%)
     
  • EUR/USD

    1.0779
    -0.0050 (-0.46%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Vix

    13.01
    +0.23 (+1.80%)
     
  • GBP/USD

    1.2602
    -0.0036 (-0.29%)
     
  • USD/JPY

    151.4450
    +0.1990 (+0.13%)
     
  • Bitcoin USD

    70,648.72
    +647.48 (+0.92%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,969.71
    +37.73 (+0.48%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates UMPQ, XLRN, ADMS, AZPN; Shareholders are Encouraged to Contact the Firm

NEW YORK, NY / ACCESSWIRE / October 21, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

Umpqua Holdings Corporation (NASDAQ:UMPQ) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Columbia Banking System, Inc. Under the terms of the agreement, Umpqua shareholders will receive 0.5958 of a share of Columbia stock for each Umpqua share they own. Upon completion of the transaction, Umpqua shareholders will own approximately 62% of the combined company. If you are an Umpqua shareholder, click here to learn more about your rights and options.

Acceleron Pharma Inc. (NASDAQ:XLRN)concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Merck & Co., Inc. for $180.00 per share in cash. If you are an Acceleron shareholder, click here to learn more about your rights and options.

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Supernus Pharmaceuticals, Inc. for $8.10 per share in cash plus two non-tradable contingent value rights collectively worth up to $1.00 per share in cash. If you are an Adamas shareholder, click here to learn more about your rights and options.

Aspen Technology, Inc. (NASDAQ:AZPN) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with certain of Emerson Electric Co.'s industrial software businesses. Under the terms of the agreement, Aspen shareholders will receive approximately $87.00 per share in cash and 0.42 shares of common stock of the combined company for each share of Aspen common stock they own. If you are an Aspen shareholder, click here to learn more about your rights and options.

Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email sadeh@halpersadeh.com or zhalper@halpersadeh.com.

Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLP
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
sadeh@halpersadeh.com
zhalper@halpersadeh.com
https://www.halpersadeh.com

SOURCE: Halper Sadeh LLP



View source version on accesswire.com:
https://www.accesswire.com/669226/SHAREHOLDER-INVESTIGATION-Halper-Sadeh-LLP-Investigates-UMPQ-XLRN-ADMS-AZPN-Shareholders-are-Encouraged-to-Contact-the-Firm

Advertisement